Stephen Robert Schmidt

US Patent:

20050172344, Aug 4, 2005

Filed:

Nov 3, 2004

Appl. No.:

10/980922

Inventors:

Ottavio Arancio - New York NY, US
Paul Mathews - Irvington NY, US
Stephen Schmidt - Nutley NJ, US
Ralph Nixon - Tarrytown NY, US
Fortunato Battaglia - New York NY, US
Fabrizio Trinchese - Rome, IT
Shumin Liu - Tappan NY, US

International Classification:

A01K067/027
C12N005/06

US Classification:

800012000, 435354000

Abstract:

The present invention describes a dissociated cell culture system comprising cells of the hippocampus, one of the brain areas affected by Alzheimer's Disease (AD) or amyloid beta-related diseases. This culture system comprises hippocampal neuronal and glial cells from animal models of AD, particularly, but not limited to, double transgenic mice expressing both the human APP mutation (K670N:M671L) (mAPP), and the human PS1 mutation (M146L) (mPS1), and serves as a powerful tool for the screening and testing of compounds and substances, e.g., drugs, for their ability to affect, treat, or prevent AD or β-amyloid-related diseases. The effects of a test substance on the cells in this culture system can be quantitatively assessed to determine if the test substance affects the cells biochemically and/or electrophysiologically, and/or optically, and/or immunocytochemically. The present in vitro culture system is advantageous for AD drug screening, because it is rapid and efficient. By contrast, even in the fastest animal model of AD, pathology does not start before the end of the second month. If such in vivo animal models are used, it is necessary to wait at least the two month time duration or longer to test for drug efficacy for AD treatment or prevention. At the same time the present invention provides a tool for production of amyloid-beta that can be used for electrophysiological, behavioral, and toxicological studies.